Related Experiment Videos
[Tumor markers used in oncology]
1Universidad Nacional Federico Villareal, Lima, Peru.
Summary
Tumor markers like hCG, AFP, and CEA are useful for monitoring specific cancers, but lack specificity for early detection. Monoclonal antibodies offer improved accuracy for cancer diagnosis and staging.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Context:
- Established tumor markers such as human chorionic gonadotropin (hCG), alpha-feto protein (AFP), and carcinoembryonic antigen (CEA) have defined roles in monitoring specific malignancies.
- Current limitations exist in the early detection of neoplasms due to the lack of specificity of these markers for cancerous versus normal tissues.
Purpose:
- To evaluate the utility of established tumor markers and explore the potential of monoclonal antibodies in cancer diagnostics.
- To address the challenges in early cancer detection and improve diagnostic accuracy.
Summary:
- Human chorionic gonadotropin (hCG), alpha-feto protein (AFP), and carcinoembryonic antigen (CEA) are key tumor markers, primarily utilized for monitoring patients with choriocarcinoma, germ cell tumors, and gastrointestinal neoplasms.
- The clinical success of tumor markers in early cancer detection is limited by their specificity. Monoclonal antibodies, generated via hybridization techniques, offer high specificity and affinity for tumor-specific antigenic determinants.
- These antibodies can detect qualitative and quantitative differences between normal and malignant cells, paving the way for improved diagnostic applications.
Impact:
- Monoclonal antibodies hold significant clinical potential for the early detection and diagnosis of cancer.
- They can enhance the accuracy of tumor staging and contribute to more effective therapeutic strategies.